The Allurion Balloon is indicated for adult patients with a body mass index of 30 to 40 in Brazil. Credit: Allurion / Business Wire.

Allurion has secured approval from Brazilian Health Regulatory Agency ANVISA to launch its gastric balloon technology in the country.

Known as the Elipse Balloon in Brazil, it is claimed to be the first and only intragastric weight-loss balloon in the world.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

It can be placed and removed without the need for surgery, endoscopy or anaesthesia.

The technology is indicated for adult patients with a body mass index (BMI) of 30 to 40 in Brazil.

The balloon will be available as part of the Allurion Program, which motivates patients to make positive lifestyle changes for long-term weight loss.

The programme includes a suite of digital tools that are designed to increase success as well as support from nutritionists and doctors.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It has been designed for individuals who cannot lose weight through dieting alone and who do not want, or are unable, to have invasive surgery or endoscopy.

The Allurion Program can also be useful for people who need to manage co-morbidities related to their weight, which can include infertility, diabetes or cardiovascular disease.

Allurion co-founder and CEO Dr Shantanu Gaur said: “Obesity represents one of the most significant health challenges in Brazil today.

“We welcome ANVISA’s approval, and we look forward to working with healthcare professionals and other weight-loss experts to end obesity in the country.”

The Allurion Balloon is marketed in 60 countries following its launch in Brazil.

Brazil currently has five clinics that provide the Allurion Program, with seven more planned to open soon.

Over the last 12 months, Allurion has also launched its technology in Mexico, Canada, Australia and India.